Tecentriq may be used with the medicines cobimetinib and vemurafenib in patients with melanoma when their skin cancer: has spread to other parts of the body or cannot be removed by surgery, and; ...

Roche’s Tecentriq With Lurbinectedin Increases Survival From Small-Cell Lung Cancer, Study Says Late-stage trials showed the combination led to a 27% reduction in the risk of death, the company said ...

In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

Tecentriq may be used with the medicine bevacizumab when a patient’s liver cancer: Has spread or cannot be removed by surgery, and; The patient has not received other medicines by mouth or ...

Tecentriq can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life ...

The Tecentriq combination showed a statistically significant improvement in RFS in t. Genentech, a unit of Roche Holdings AG (OTC: RHHBY), ...

Tecentriq is available as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). You’ll receive infusions at your doctor’s office or a clinic.

“Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity ...

Tecentriq with chemotherapy did not significantly improve EFS in TNBC patients, with a four-year EFS rate of 85.2% versus 81.9% for placebo. No overall survival benefit was observed with Tecentriq, ...

Roche has voluntarily withdrawn the U.S. indication of Tecentriq for treating a form of bladder cancer following consultation with the Food and Drug Administration (FDA), the Swiss drugmaker said ...

Zepzelca plus Tecentriq improved PFS and OS in ES-SCLC patients compared to Tecentriq alone, with a median PFS of 5.4 months versus 2.1 months. The combination therapy showed a median OS of 13.2 ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...